Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study

Abstract

Aims We aimed to assess and characterize sex differences in adverse drug reactions (ADRs) reported to the national pharmacovigilance centre in the Netherlands while considering differences in drug use. Methods ADRs spontaneously reported by healthcare professionals and patients to the Netherlands pharmacovigilance centre Lareb were used. Drug–ADR combinations reported at least 10 times between 2003–2016 for drugs used by ≥10,000 persons in that period were included. Data about the number of drug users was obtained from the National Health Care Institute. Sex‐specific ADRs, like gynaecological problems, were excluded. Sex differences in specific drug–ADR combinations were tested using bivariate logistic regression analyses in which the number of drug users per sex was taken into account. Results In total, 2483 drug–ADR combinations were analysed. Possibly relevant sex differences were shown in 363 combinations (15%). Most of these drug–ADR combinations were reported more often for women (322 combinations). Drugs with the highest number of ADRs that were more often reported for women included thyroid hormones (32 combinations) and antidepressants (16 combinations for the centrally acting sympathomimetics; 14 combinations for other antidepressants). Some ADRs were predominantly reported for women across a range of drugs such as headache and dizziness whereas other ADRs such as tendon ruptures and aggression were reported more often for men. Conclusions Identified sex differences in reported ADRs often referred to women. These differences may have various causes, including pharmacological and behavioural causes, which need to be further assessed. The results may ultimately lead to sex‐specific prescribing or monitoring recommendations.

Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study

“…The reduction of sex differences in ADR reporting over time was accompanied by a lower dose of metformin among women at later stages after initiation. Previous studies indicate that women more often report an ADR than men for drugs in general [15][16][17][18], as well as for metformin specifically [5,19]. The current study adds to this knowledge that sex differences in metformin-associated ADRs are particularly shown at early stages after initiation.…”

“…A previous study showed that ADRs experienced by people with diabetes can be transient or fluctuating over time [22] but it is not clear whether this differs between men and women. This could in part be a gender-related factor, since social, behavioral, and cultural differences between men and women may influence the experience and reporting of ADRs [15,23,24]. Women and men have different risk perceptions [25] and it has been shown that women more often read patient information leaflets than men [26].…”

Making medicines safer: analysis of patient reports to the UK’s Yellow Card Scheme

“…However, the study also found differences in the drugs which were cited between the genders, particularly for endocrine, anti-infective and cardiovascular medicines. Differences in drugs and reported symptoms between the sexes have previously been shown in large-scale studies [27,28]. In addition, females were more likely to report serious reactions and to include more reaction terms in reports than males.…”

Individualized medicine: Sex, hormones, genetics, and adverse drug reactions

“…A "possibly relevant" sex difference was identified in 15% of the drug-ADR combinations after accounting for differences in medication use; the risk was higher for women than men in 89% of cases. 9 If personalized medicine is to become a reality, it is critical to understand not only interindividual genetic differences, but also underlying F I G U R E 1 Volcano plot of adverse drug event signals. In the volcano plot of ADE signals, the signal detection result shows the magnitude (log2 reporting odds ratio [ROR], x-axis) and significance (−log10 adjusted P value, y-axis) for sexdrug-event combinations associations of specific drugs.…”